Patents by Inventor Nicole Deglon

Nicole Deglon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alzheimer's disease animal model
    Patent number: 10986821
    Abstract: The present invention relates to a vector comprising a nucleic acid sequence that encodes the APP protein and/or the PS1 protein or variants thereof. The invention also relates to a method for inducing the Alzheimer's disease in an animal using the vector of the invention and to animal model having the Alzheimer's disease obtained by said method.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: April 27, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Paris—Sud, Commissariat a l'Energie Atomique et aux Energies Alternatives, Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes
    Inventors: Nathalie Cartier-Lacave, Jerome Braudeau, Nicole Deglon, Philippe Hantraye, Mickael Audrain
  • NEW ALZHEIMER'S DISEASE ANIMAL MODEL
    Publication number: 20190183102
    Abstract: The present invention relates to a vector comprising a nucleic acid sequence that encodes the APP protein and/or the PS1 protein or variants thereof. The invention also relates to a method for inducing the Alzheimer's disease in an animal using the vector of the invention and to animal model having the Alzheimer's disease obtained by said method.
    Type: Application
    Filed: November 2, 2018
    Publication date: June 20, 2019
    Inventors: Nathalie Cartier-Lacave, Jerome Braudeau, Nicole Deglon, Philippe Hantraye, Mickael Audrain
  • Alzheimer's disease animal model
    Patent number: 10159227
    Abstract: The present invention relates to a vector comprising a nucleic acid sequence that encodes the APP protein and/or the PS1 protein or variants thereof. The invention also relates to a method for inducing the Alzheimer's disease in an animal using the vector of the invention and to animal model having the Alzheimer's disease obtained by said method.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: December 25, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Paris—Sud, Commissariat a l'Energie Atomique et aux Energies Alternatives, Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes
    Inventors: Nathalie Cartier-Lacave, Jerome Braudeau, Nicole Deglon, Philippe Hantraye, Mickael Audrain
  • GENOME EDITING FOR THE TREATMENT OF HUNTINGTON'S DISEASE
    Publication number: 20170224843
    Abstract: A treatment of Huntington's disease (HD) using the Clustered-Regularly Interspaced Short Palindromic Repeats (CRISPR) system. This technology offers the possibility to design a small RNA (sgRNA), which is incorporated into a CRISPR-associated protein (Cas9) to recognize and induce DNA double-strand breaks at a specific target location. In the context of HD, this allows to block the expression of the mutant huntingtin or repair the CAG expansion causing the disease.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 10, 2017
    Applicant: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)
    Inventors: Nicole DEGLON, Nicolas MERIENNE
  • Vector for the selective silencing of a gene in astrocytes
    Patent number: 9695443
    Abstract: The present invention relates to a viral vector for silencing a gene specifically in astrocytes comprising: —an astrocyte-specific viral envelope protein, —a first nucleic acid sequence encoding a transcription activator and at least one target sequence of a neuron-specific miR under the control of an astrocyte-specific promoter, and—a second nucleic acid sequence encoding a RNA for silencing the gene under the control of a promoter inducible by the transcription activator.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: July 4, 2017
    Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventor: Nicole Deglon
  • NEW ALZHEIMER'S DISEASE ANIMAL MODEL
    Publication number: 20160262361
    Abstract: The present invention relates to a vector comprising a nucleic acid sequence that encodes the APP protein and/or the PS1 protein or variants thereof. The invention also relates to a method for inducing the Alzheimer's disease in an animal using the vector of the invention and to animal model having the Alzheimer's disease obtained by said method.
    Type: Application
    Filed: November 5, 2014
    Publication date: September 15, 2016
    Inventors: Nathalie Cartier-Lacave, Jerome Braudeau, Nicole Deglon, Philippe Hantraye, Mickael Audrain
  • VECTOR FOR THE SELECTIVE SILENCING OF A GENE IN ASTROCYTES
    Publication number: 20150159171
    Abstract: The present invention relates to a viral vector for silencing a gene specifically in astrocytes comprising:—an astrocyte-specific viral envelope protein,—a first nucleic acid sequence encoding a transcription activator and at least one target sequence of a neuron-specific miR under the control of an astrocyte-specific promoter, and—a second nucleic acid sequence encoding a RNA for silencing the gene under the control of a promoter inducible by the transcription activator.
    Type: Application
    Filed: May 24, 2013
    Publication date: June 11, 2015
    Inventor: Nicole Deglon
  • Use of IL-6/IL-6 chimera in Huntington's disease
    Patent number: 8329654
    Abstract: The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: December 11, 2012
    Assignee: Ares Trading S.A.
    Inventors: Nicole Deglon, Patrick Aebischer, Jean-Charles Bensadoun
  • Reversible siRNA-based silencing of mutant and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease
    Patent number: 8217018
    Abstract: Isolated double-stranded short interfering nucleic acid molecules inhibiting the expression of endogenous wild-type and exogenous human mutant huntintin genes in cells of a non-human mammal which are expressing both said huntingtin genes, and their application for the treatment of Huntington's disease as well as to study Huntington's disease in rodent models.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: July 10, 2012
    Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventors: Valérie Perrin, Nicole Deglon
  • Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease
    Publication number: 20100299768
    Abstract: Isolated double-stranded short interfering nucleic acid molecules inhibiting the expression of endogenous wild-type and exogenous human mutant huntintin genes in cells of a non-human mammal which are expressing both said huntingtin genes, and their application for the treatment of Huntington's disease as well as to study Huntington's disease in rodent models.
    Type: Application
    Filed: June 18, 2008
    Publication date: November 25, 2010
    Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE
    Inventors: Valerie Perrin, Nicole Deglon
  • USE OF IL-6/IL-6 CHIMERA IN HUNTINGTON'S DISEASE
    Publication number: 20100166703
    Abstract: The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.
    Type: Application
    Filed: March 4, 2010
    Publication date: July 1, 2010
    Applicant: ARES TRADING S.A.
    Inventors: NICOLE DEGLON, PATRICK AEBISCHER, JEAN-CHARLES BENSADOUN
  • USE OF IL-6/IL-6 CHIMERA IN HUNTINGTON'S DISEASE
    Publication number: 20070172454
    Abstract: The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.
    Type: Application
    Filed: January 11, 2007
    Publication date: July 26, 2007
    Applicant: ARES TRADING S.A.
    Inventors: Nicole Deglon, Patrick Aebischer, Jean-Charles Bensadoun
  • Use of il-6r/il-6 chimera in huntington's disease
    Publication number: 20040057928
    Abstract: The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.
    Type: Application
    Filed: September 16, 2003
    Publication date: March 25, 2004
    Inventors: Nicole Deglon, Patrick Aebischer, Jean-Charles Bensadoun
  • Hypoxia responsive EPO producing cells
    Patent number: 5952226
    Abstract: A device and method for delivery of EPO to a patient using an implanted device that continuously releases EPO.
    Type: Grant
    Filed: May 9, 1997
    Date of Patent: September 14, 1999
    Assignee: Modex therapeutiques
    Inventors: Patrick Aebischer, Nicole Deglon, Etienne Regulier, Christopher Rinsch